Consensus Recommendations for the Diagnosis, Biomarker Testing, and Clinical Management of Advanced or Metastatic Non-small Cell Lung Cancer With Mesenchymal-Epithelial Transition Exon 14 Skipping Mutations in the Middle East, Africa, and Russia

Basit Öğe Kaydı
dc.authorwosidSendur, Mehmet Ali Nahit/H-7555-2014
dc.contributor.authorMahrous, Mervat
dc.contributor.authorJebriel, Abdalla Omar
dc.contributor.authorAllehebi, Ahmed
dc.contributor.authorShafik, Amr
dc.contributor.authorEl Karak, Fadi
dc.contributor.authorVenturini, Filippo
dc.contributor.authorAlhusaini, Hamed
dc.date.accessioned2024-05-19T14:46:01Z
dc.date.available2024-05-19T14:46:01Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractMesenchymal-epithelial transition exon 14 (METex14) skipping mutations occur in about 3%-4% of patients with non-small cell lung cancer (NSCLC). This is an aggressive subtype associated with poor prognosis. METex14 skipping is a potentially targetable mutation. Targeted therapy is a promising treatment modality for patients with advanced/metastatic METex14-mutant NSCLC. Performing systematic molecular testing to detect the driver mutation is essential for initiating targeted therapy. However, there is a lack of guidelines on molecular testing for assessing the eligibility of patients for targeted therapy. Therefore, a multidisciplinary panel consisting of experts from the Middle East, Africa, and Russia convened via a virtual advisory board meeting to provide their insights on various molecular testing techniques for the diagnosis of METex14 skipping mutation, management of patients with targeted therapies, and developing consensus recommendations for improving the processes. The expert panel emphasized performing molecular testing and liquid biopsy before treatment initiation and tissue re-biopsy for patients with failed molecular testing. Liquid biopsy was recommended as complementary to tissue biopsy for disease monitoring and prognosis. Selective MET inhibitors were recommended as the first and subsequent lines of therapy. These consensus recommendations will facilitate the management of METex14 skipping NSCLC in routine practice and warrant optimum outcomes for these patients.en_US
dc.description.sponsorshipMerck Serono, Middle East FZ-Ltd, Dubai, UAE, an affiliate of Merck KGaA Darmstadt, Germanyen_US
dc.description.sponsorship& nbsp;Writing assistance and editorial support were provided by Salini Asok and Somdatta Mukherjee from Turacoz Healthcare Solutions ( www.turacoz.com ) and funded by Merck Serono, Middle East FZ-Ltd, Dubai, UAE, an affiliate of Merck KGaA Darmstadt, Germany.en_US
dc.identifier.doi10.7759/cureus.41992
dc.identifier.issn2168-8184
dc.identifier.issue7en_US
dc.identifier.pmid37492039en_US
dc.identifier.urihttps://doi.org10.7759/cureus.41992
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5421
dc.identifier.volume15en_US
dc.identifier.wosWOS:001048091700005en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherSpringernatureen_US
dc.relation.ispartofCureus Journal of Medical Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectNon-Small-Cell Lung Canceren_US
dc.subjectTargeted Therapyen_US
dc.subjectOverall Survivalen_US
dc.subjectNext-Generation Sequencingen_US
dc.subjectMet Tyrosineen_US
dc.subjectKinase Inhibitorsen_US
dc.subjectMet Exon 14 Skipping Mutationen_US
dc.subjectLung Canceren_US
dc.subjectLiquid Biopsyen_US
dc.subjectImmunotherapyen_US
dc.subjectChemotherapyen_US
dc.titleConsensus Recommendations for the Diagnosis, Biomarker Testing, and Clinical Management of Advanced or Metastatic Non-small Cell Lung Cancer With Mesenchymal-Epithelial Transition Exon 14 Skipping Mutations in the Middle East, Africa, and Russiaen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu